KHẢO SÁT THỰC TRẠNG SỬ DỤNG THUỐC KHÁNG SINH TRONG ĐIỀU TRỊ VIÊM PHỔI BỆNH VIỆN TẠI BỆNH VIỆN CHỢ RẪY GIAI ĐOẠN 2021 – 2022

Abstract

Background: Hospital-acquired pneumonia (HAP) is a common disease with a very high prevalence worldwide and the treatment is often ineffective, which can lead to death. Antibiotics are one of the important interventions in the treatment and control of infections. Therefore, a survey on the actual use of antibiotics in the treatment of HAP is necessary. Objectives: Survey on the situation of antibiotic use in the treatment of hospital-acquired pneumonia at Cho Ray hospital in the period of 2021 - 2022. Materials  and  methods: Cross-sectional descriptive study was conducted through retrospective medical records at Cho Ray Hospital in the period of 2021 - 2022. Results: Patients with hospital-acquired pneumonia are mostly aged > 65 years old (accounting for 59.9%) with a male:female ratio of 1.58:1. Patients receiving a health insurance coverage of 80% account for 57.7%; 55.1% of patients had a treatment outcome of improvement, which is a high proportion; 61.0% of patients were treated in the internal medicine department. 98.3% of patients were prescribed a combination regimen of two or more drugs, with the fluoroquinolone being the most prescribed group with 19.6% and meropenem being the most prescribed drug with 14.9%. Conclusion: Combination regimens are the majority, and the fluoroquinolone group and the active ingredient meropenem are the most prescribed in the treatment of hospital-acquired pneumonia.